Results of Macitentan in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension　― A Prospective, Multicenter, Open-Label, Single-Arm, Phase 3 Study ―

Background: Macitentan, an endothelin-receptor antagonist, is approved in Japan for the treatment of pulmonary arterial hypertension (PAH). This study evaluated the use of macitentan for chronic thromboembolic pulmonary hypertension (CTEPH) in Japanese patients. Methods and Results: This open-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Satomi, Ukyo, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258181/
https://www.ncbi.nlm.nih.gov/pubmed/34250282
http://dx.doi.org/10.1253/circrep.CR-21-0034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258181/
https://www.ncbi.nlm.nih.gov/pubmed/34250282
http://dx.doi.org/10.1253/circrep.CR-21-0034

Ejemplares similares